Abstract
High-molecular-weight (HMW) adiponectin has important antiatherosclerotic properties. This study compared circulating HMW adiponectin concentrations and other parameters between patients with coronary artery disease (CAD) and participants without CAD. We investigated whether treatment with statins and either telmisartan or enalapril might affect HMW adiponectin and other parameters in patients with CAD. Finally, adiponectin concentrations were compared after 6 months of treatment between CAD patients with versus without cardiac events. Consecutive patients with stable CAD admitted to our hospital (Iwate Medical University School of Medicine, Iwate, Japan) for percutaneous coronary intervention (PCI) and stent implantation and with no previous treatment with renin-angiotensin system blockers or statins were recruited. Patients with CAD who met all eligibility criteria were randomly assigned using computer-generated numbers in a 1:1 ratio to receive telmisartan (40 mg/d) or enalapril (5 mg/d) for 6 months. In addition, all patients with CAD were treated with atorvastatin (10 mg/d). The patients without CAD received no treatment with telmisartan, enalapril, or atorvastatin. Plasma concentrations of total and HMW adiponectin were m...Continue Reading
References
Feb 1, 1992·Internal Medicine·A KobayashiN Yamazaki
Mar 25, 2000·The New England Journal of Medicine·P M RidkerN Rifai
Jun 17, 2000·Diabetes Care·E BonoraM Muggeo
Feb 15, 2001·Circulation·B HornigH Drexler
Feb 27, 2001·Circulation·N OuchiY Matsuzawa
May 10, 2001·The Journal of Clinical Endocrinology and Metabolism·C WeyerP A Tataranni
Aug 28, 2001·Diabetes·N MaedaY Matsuzawa
Oct 9, 2002·Nature Medicine·T YamauchiT Kadowaki
Nov 15, 2002·The Journal of Biological Chemistry·Toshimasa YamauchiTakashi Kadowaki
Dec 24, 2002·The Journal of Biological Chemistry·Utpal B PajvaniPhilipp E Scherer
Jan 28, 2003·Lancet·Joachim SprangerAndreas F H Pfeiffer
Mar 4, 2003·European Journal of Endocrinology·Juan J Díez, Pedro Iglesias
Oct 3, 2003·The Journal of Biological Chemistry·Tsu-Shuen TsaoHarvey F Lodish
Jan 31, 2004·Circulation Research·Hideki KobayashiYuji Matsuzawa
Mar 10, 2004·Hypertension·Stephen C BensonTheodore W Kurtz
May 1, 2004·Circulation·Michael SchuppUlrich Kintscher
Oct 23, 2004·FEBS Letters·Muneya FujimotoKazuwa Nakao
Apr 22, 2005·The New England Journal of Medicine·Göran K Hansson
May 16, 2006·Clinica Chimica Acta; International Journal of Clinical Chemistry·Hiroyuki EbinumaTakashi Kadowaki
Jun 29, 2006·Diabetes·Yoshimasa AsoYasuko Nakano
Sep 15, 2006·Atherosclerosis·Ascan WarnholtzThomas Munzel
Aug 19, 2007·The American Journal of Cardiology·Teruo InoueKoichi Node
Nov 10, 2007·Circulation Research·Yoshihisa OkamotoPeter Libby
Jan 15, 2008·International Journal of Cardiology·Jin YokoyamaKen Okumura
Feb 12, 2008·European Heart Journal·Renate SchnabelStefan Blankenberg
Citations
Aug 26, 2014·Journal of the American Society of Hypertension : JASH·Hisato TakagiUNKNOWN All-Literature Investigation of Cardiovascular Evidence Group
Feb 23, 2012·International Journal of Cardiology·Hisato TakagiTakuya Umemoto
Jan 13, 2015·Atherosclerosis. Supplements·Lorenzo Arnaboldi, Alberto Corsini
Oct 6, 2016·PloS One·Hiroki AdachiHitoshi Yokoyama
Sep 3, 2010·Current Opinion in Pharmacology·Susan A Phillips, Jacqueline T Kung
Sep 2, 2011·Arquivos brasileiros de endocrinologia e metabologia·Amirhossein Sahebkar
Jul 20, 2014·Therapeutic Advances in Cardiovascular Disease·Edu Suarez-MartinezLeon Ferder
Jan 1, 2014·Environmental Toxicology and Chemistry·Ryan S ProsserPaul K Sibley
Aug 20, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sudeep PushpakomUNKNOWN TAILoR Study Group